175 related articles for article (PubMed ID: 27122234)
1. Preclinical Evaluation of an Anti-Nectin-4 ImmunoPET Reagent in Tumor-Bearing Mice and Biodistribution Studies in Cynomolgus Monkeys.
Campbell DO; Noda A; Verlinsky A; Snyder J; Fujita Y; Murakami Y; Fushiki H; Miyoshi S; Lacayo S; Cabral E; Yang P; Stover DR; Joseph IB
Mol Imaging Biol; 2016 Oct; 18(5):768-75. PubMed ID: 27122234
[TBL] [Abstract][Full Text] [Related]
2. Fc engineering of anti-Nectin-2 antibody improved thrombocytopenic adverse event in monkey.
Oshima T; Miyashita H; Ishimura Y; Ito Y; Tanaka Y; Hori A; Kokubo T; Kurokawa T
PLoS One; 2018; 13(5):e0196422. PubMed ID: 29723247
[TBL] [Abstract][Full Text] [Related]
3. What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between
Bailly C; Gouard S; Guérard F; Chalopin B; Carlier T; Faivre-Chauvet A; Remaud-Le Saëc P; Bourgeois M; Chouin N; Rbah-Vidal L; Tripier R; Haddad F; Kraeber-Bodéré F; Bodet-Milin C; Chérel M
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137758
[TBL] [Abstract][Full Text] [Related]
4. ImmunoPET Imaging of Endogenous and Transfected Prolactin Receptor Tumor Xenografts.
Cheal SM; Ruan S; Veach DR; Longo VA; Punzalan BJ; Wu J; Fung EK; Kelly MP; Kirshner JR; Giurleo JT; Ehrlich G; Han AQ; Thurston G; Olson WC; Zanzonico PB; Larson SM; Carrasquillo JA
Mol Pharm; 2018 Jun; 15(6):2133-2141. PubMed ID: 29684277
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of 89Zr-labeled anti-CD44 monoclonal antibody RG7356 in mice and cynomolgus monkeys: Prelude to Phase 1 clinical studies.
Vugts DJ; Heuveling DA; Stigter-van Walsum M; Weigand S; Bergstrom M; van Dongen GA; Nayak TK
MAbs; 2014; 6(2):567-75. PubMed ID: 24492295
[TBL] [Abstract][Full Text] [Related]
6. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.
Challita-Eid PM; Satpayev D; Yang P; An Z; Morrison K; Shostak Y; Raitano A; Nadell R; Liu W; Lortie DR; Capo L; Verlinsky A; Leavitt M; Malik F; Aviña H; Guevara CI; Dinh N; Karki S; Anand BS; Pereira DS; Joseph IB; Doñate F; Morrison K; Stover DR
Cancer Res; 2016 May; 76(10):3003-13. PubMed ID: 27013195
[TBL] [Abstract][Full Text] [Related]
7. Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers.
Oshima T; Sato S; Kato J; Ito Y; Watanabe T; Tsuji I; Hori A; Kurokawa T; Kokubo T
Mol Cancer; 2013 Jun; 12():60. PubMed ID: 23758976
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Anti-LGR5 Antibodies by ImmunoPET for Imaging Colorectal Tumors and Development of Antibody-Drug Conjugates.
Azhdarinia A; Voss J; Ghosh SC; Simien JA; Hernandez Vargas S; Cui J; Yu WA; Liu Q; Carmon KS
Mol Pharm; 2018 Jun; 15(6):2448-2454. PubMed ID: 29718672
[TBL] [Abstract][Full Text] [Related]
9. ImmunoPET imaging of tissue factor expression in pancreatic cancer with
Hernandez R; England CG; Yang Y; Valdovinos HF; Liu B; Wong HC; Barnhart TE; Cai W
J Control Release; 2017 Oct; 264():160-168. PubMed ID: 28843831
[TBL] [Abstract][Full Text] [Related]
10. Preclinical 89Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis.
Sharma SK; Sevak KK; Monette S; Carlin SD; Knight JC; Wuest FR; Sala E; Zeglis BM; Lewis JS
J Nucl Med; 2016 May; 57(5):771-6. PubMed ID: 26837339
[TBL] [Abstract][Full Text] [Related]
11. ImmunoPET Imaging of Insulin-Like Growth Factor 1 Receptor in a Subcutaneous Mouse Model of Pancreatic Cancer.
England CG; Kamkaew A; Im HJ; Valdovinos HF; Sun H; Hernandez R; Cho SY; Dunphy EJ; Lee DS; Barnhart TE; Cai W
Mol Pharm; 2016 Jun; 13(6):1958-66. PubMed ID: 27054683
[TBL] [Abstract][Full Text] [Related]
12. ImmunoPET Imaging of CD47 with VHH-Derived Tracers in Pancreatic Cancers.
Liang C; Huang W; Zhang Y; Zhang D; An S; Wu Q; Zhao H; Wang C; Huang G; Wei W; Liu J
Mol Pharm; 2023 Aug; 20(8):4184-4195. PubMed ID: 37403817
[TBL] [Abstract][Full Text] [Related]
13. ImmunoPET imaging of CD38 in murine lymphoma models using
Kang L; Jiang D; England CG; Barnhart TE; Yu B; Rosenkrans ZT; Wang R; Engle JW; Xu X; Huang P; Cai W
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1372-1381. PubMed ID: 29450576
[TBL] [Abstract][Full Text] [Related]
14. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Pharmacokinetics Evaluation of Anti-heparin-binding EGF-like Growth Factor (HB-EGF) Monoclonal Antibody Using Cynomolgus Monkeys via (89)Zr-immuno-PET Study and the Determination of Drug Concentrations in Serum and Cerebrospinal Fluid.
Kasai N; Adachi M; Yamano K
Pharm Res; 2016 Feb; 33(2):476-86. PubMed ID: 26464296
[TBL] [Abstract][Full Text] [Related]
16. ImmunoPET Imaging of CD146 Expression in Malignant Brain Tumors.
Hernandez R; Sun H; England CG; Valdovinos HF; Barnhart TE; Yang Y; Cai W
Mol Pharm; 2016 Jul; 13(7):2563-70. PubMed ID: 27280694
[TBL] [Abstract][Full Text] [Related]
17. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging.
Dijkers EC; Kosterink JG; Rademaker AP; Perk LR; van Dongen GA; Bart J; de Jong JR; de Vries EG; Lub-de Hooge MN
J Nucl Med; 2009 Jun; 50(6):974-81. PubMed ID: 19443585
[TBL] [Abstract][Full Text] [Related]
18. Preclinical development of ZED8, an
Ogasawara A; Kiefer JR; Gill H; Chiang E; Sriraman S; Ferl GZ; Ziai J; Bohorquez SS; Guelman S; Wang X; Yang J; Phan MM; Nguyen V; Chung S; Yu C; Tinianow J; Waaijer SJH; De Crespigny A; Marik J; Boswell CA; Zabka T; Staflin K; Williams SP
Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):287-301. PubMed ID: 36271158
[TBL] [Abstract][Full Text] [Related]
19. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
[TBL] [Abstract][Full Text] [Related]
20. EGFR-Targeted ImmunoPET of UMUC3 Orthotopic Bladder Tumors.
Hoang TT; Mandleywala K; Viray T; Tan KV; Lewis JS; Pereira PMR
Mol Imaging Biol; 2022 Aug; 24(4):511-518. PubMed ID: 35147837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
